INBP
Integrated BioPharma, Inc. OTC$0.24
Mkt Cap $7.5M
52w Low $0.21
14.3% of range
52w High $0.42
50d MA $0.28
200d MA $0.30
P/E (TTM)
9.0x
EV/EBITDA
2.4x
P/B
0.4x
Debt/Equity
0.1x
ROE
-0.4%
P/FCF
5.8x
RSI (14)
—
ATR (14)
—
Beta
0.55
50d MA
$0.28
200d MA
$0.30
Avg Volume
6.9K
About
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale t…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | AMC | — | -0.03 | — | 0.30 | -6.7% | +3.3% | -0.1% | +0.0% | -0.4% | -0.8% | — |
| Nov 10, 2025 | AMC | — | 0.00 | — | 0.31 | -4.7% | -6.4% | -8.2% | -7.4% | -14.8% | +0.0% | — |
| Sep 23, 2025 | AMC | — | -0.01 | — | 0.33 | -3.0% | -3.0% | -6.1% | -9.1% | -11.5% | -12.1% | — |
| May 14, 2025 | AMC | — | 0.02 | — | 0.29 | +7.2% | +14.1% | +17.5% | +20.9% | +21.0% | +14.1% | — |
| Feb 13, 2025 | AMC | — | 0.00 | — | 0.26 | +28.0% | +14.5% | +6.9% | +6.9% | +24.2% | +26.0% | — |
| Nov 13, 2024 | AMC | — | 0.01 | — | 0.32 | +4.7% | +9.4% | +6.2% | -9.4% | +6.2% | +5.8% | — |
| Sep 20, 2024 | AMC | — | 0.01 | — | 0.23 | +0.9% | +9.6% | +9.6% | +9.6% | +9.6% | +9.6% | — |
| May 10, 2024 | AMC | — | 0.01 | — | — | — | — | — | — | — | — | — |
| Feb 12, 2024 | AMC | — | -0.01 | — | 0.23 | -8.7% | -13.0% | -0.0% | +0.0% | +0.0% | +0.0% | — |
| Nov 9, 2023 | AMC | — | -0.00 | — | 0.27 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -1.9% | — |
Recent Filings
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
INBP's material event announcement lacks sufficient detail in this filing excerpt to assess impact, but investors should monitor the company's next disclosure for clarification on what triggered this 8-K.
Apr 15
8-K
INTEGRATED BIOPHARMA INC -- 8-K Filing
Integrated Biopharma amended its vitamin realty lease agreement with Vitamin Realty Associates, likely adjusting facility terms or rental obligations for its Manhattan Drug Company subsidiary operations.
Feb 18
8-K
INTEGRATED BIOPHARMA INC -- 8-K Filing
I cannot write a meaningful analysis sentence from this filing excerpt, as it only contains signature page boilerplate without substantive information about any transaction or event affecting Integrated Biopharma Inc.
Feb 11
Data updated apr 28, 2026 12:07pm
· Source: massive.com